Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520618 | 0.87 | FPR2 (0.53) | FPR2POLBNAMPTALDH1A1EPHX2 | |
| SCHEMBL5526419 | 0.85 | EPHX2 (0.59) | FPR2POLBEPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL5521787 | 0.81 | PKM (0.53) | NAMPTALDH1A1PKMHTTSMN1; SMN2 | |
| SCHEMBL5518423 | 0.76 | KMT2A (0.57) | POLBALDH1A1PKMNPC1RAB9A | |
| SCHEMBL22201003 | 0.76 | EPHX2 (0.66) | POLBNAMPTALDH1A1EPHX2NPC1 | |
| SCHEMBL5532684 | 0.76 | PARP1 (0.53) | ALDH1A1PKMNPC1SMN1; SMN2 | |
| SCHEMBL7453800 | 0.75 | EPHX1 (0.70) | FPR2POLBNAMPTALDH1A1EPHX2 | |
| SCHEMBL5532544 | 0.75 | NPY5R (0.66) | POLBALDH1A1EPHX2NPC1RAB9A | |
| SCHEMBL5525522 | 0.75 | NPY5R (0.54) | POLBALDH1A1EPHX2PKMHTT | |
| SCHEMBL5526277 | 0.74 | PARP15 (0.47) | POLBNAMPTEPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | FPR2 2332/4885POLB 2141/4885NAMPT 244/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | FPR2 2075/4885POLB 2271/4885NAMPT 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.